Literature DB >> 6124428

Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics.

K S Kendler, H S Bracha, K L Davis.   

Abstract

Neuroleptic drugs have been shown to block brain dopamine (DA) receptors. The relative potency of neuroleptics at blocking DA postsynaptic receptors (PSRs) and autoreceptors (ARs) is less clear. To examine this question, the potency of 5 neuroleptics at inhibiting receptors (PSRs) and autoreceptors (ABs) is less clear. To examine this question, the potency of 5 neuroleptics at inhibiting the augmentation of mouse climbing behavior induced by a high dose of apomorphine (2.5 mg/kg) (presumably mediated by DA PSRs) was compared with their potency at inhibiting the suppression of climbing behavior induced by a low dose of apomorphine (0.45 mg/kg) (presumably mediated by DA Ars). Haloperidol and molindone had no AR-blocking ability even at doses that substantially blocked DA PSRs. Metoclopramide and fluphenazine had AR-blocking ability only at doses that produced substantial PSR blockade. Sulpiride blocked DA ARs at doses that had relatively litter PSR effect. It is concluded that neuroleptic drugs differ substantially in their relative potency at blocking DA ARs and PSRs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124428     DOI: 10.1016/0014-2999(82)90627-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  D1 and D2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse.

Authors:  S Cabib; C Castellano; V Cestari; U Filibeck; S Puglisi-Allegra
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 2.  Do autoreceptors mediate dopamine agonist--induced yawning and suppression of exploration? A critical review.

Authors:  L Ståhle
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Apomorphine-induced context-specific behavioural sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and uncoupled from contextual cues by the D2 antagonist sulpiride.

Authors:  Flávia Regina Cruz Dias; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2010-02-23       Impact factor: 4.530

4.  Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.

Authors:  E S Prosser; R Pruthi; J G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Dopamine D-2 antagonists reverse apomorphine-induced decreased water intake in the rat: prediction of antipsychotic drugs with few extrapyramidal side-effects?

Authors:  T Ljungberg
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

6.  Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.

Authors:  M R Zarrindast; M Poursoltan
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

7.  Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat.

Authors:  J M Monti; M Hawkins; H Jantos; L D'Angelo; M Fernández
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Time course of rat motility response to apomorphine: a simple model for studying preferential blockade of brain dopamine receptors mediating sedation.

Authors:  N Montanaro; A Vaccheri; R Dall'Olio; O Gandolfi
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.

Authors:  J Arnt; K P Bøgesø; A V Christensen; J Hyttel; J J Larsen; O Svendsen
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Sulpiride blocks postsynaptic dopamine receptors in the nucleus accumbens.

Authors:  R Morgenstern; H Fink
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.